Drugs / ASP8374
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04826393 | Mar → Oct 2022 | glioblastoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT03945253 | Aug 2019 → Jun 2020 | cancer | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT03260322 | Sep 2017 → May 2022 | cancer | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP8374 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03945253 ↗ |
| Known as | PTZ-201 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297894 ↗ |
| Action | Inhibit | “T-cell immunoreceptor with Ig and ITIM domains antagonist” CHEMBL4297894 ↗ |
| Route | Intravenous | “Participants received ASP8374 0.5 mg intravenously” NCT03260322 ↗ |
| Target | TIGIT | “T-cell immunoreceptor with Ig and ITIM domains antagonist” CHEMBL4297894 ↗ |